CTX-M-3 extended-spectrum beta-lactamase in a Shigella sonnei clinical isolate: first report from Turkey.
A Shigella sonnei strain resistant to cefotaxime and aztreonam (but not ceftazidime) was isolated from the stool sample of a 7-y-old outpatient. Double disk synergy test, isoelectric focusing, polymerase chain reaction and sequence analysis confirmed that the isolate produced CTX-M-3, an extended-spectrum beta-lactamase (ESBL). This is the first report from Turkey of Shigella spp. producing an ESBL, and of CTX-M type enzyme.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001483:Base Sequence; D002648:Child; D024901:Drug Resistance, Multiple, Bacterial; D004405:Dysentery, Bacillary / Q000175:diagnosis* / Q000188:drug therapy; D005243:Feces / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D012764:Shigella sonnei / Q000187:drug effects / Q000201:enzymology* / Q000302:isolation & purification; D014421:Turkey; D001618:beta-Lactamases / Q000378:metabolism*
D000900:Anti-Bacterial Agents; C417271:beta-lactamase CTX-M-3; D001618:beta-Lactamases